Clinical DataBarzolvolimab demonstrates an attractive balance of efficacy and safety with long-term treatment.
Clinical DevelopmentBarzolvolimab holds the most compelling clinical profile to date across two large Phase 2 urticaria studies, and is meaningfully ahead of competitors with enrollment well underway in the Phase 3 EMBARQ trials.
Financial StabilityCelldex ended the quarter with $673.3 million in cash, which management believes should fund all ongoing operations through 2027.